Seaport Therapeutics Announces Positive Clinical Data for GlyphAgo
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 02 2026
0mins
Source: Newsfilter
- Clinical Trial Success: Seaport Therapeutics reported positive topline data from its GlyphAgo clinical trial, demonstrating a 6.8-fold increase in bioavailability compared to unmodified agomelatine, exceeding the expected 2-fold target, indicating GlyphAgo's potential in treating generalized anxiety disorder (GAD).
- Good Safety Profile: GlyphAgo exhibited good tolerability across all evaluated doses in the trial, with no serious adverse events or liver-related side effects reported, enhancing its safety profile and potential market acceptance.
- Follow-up Trial Plans: Based on the trial results, Seaport plans to advance GlyphAgo into two parallel clinical trials, including a Phase 2a trial to assess its potential sleep benefits in GAD patients and a registration-enabling Phase 2b randomized controlled trial, further validating its clinical application.
- Platform Advantages: GlyphAgo leverages Seaport's Glyph platform to avoid first-pass liver metabolism, enhancing systemic exposure to agomelatine while reducing liver exposure risks, positioning it as a leading treatment option for GAD and addressing unmet market needs.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
